<DOC>
	<DOCNO>NCT02881476</DOCNO>
	<brief_summary>The goal study investigate safety tolerability allogeneic Wharton 's jelly-derived mesenchymal stem cell administration individual diagnose amyotrophic lateral sclerosis .</brief_summary>
	<brief_title>Therapeutic Treatment Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>Amyotrophic lateral sclerosis ( ALS ) one progressive neurodegenerative disorder , affect upper low motor neuron cerebral cortex , brainstem spinal cord . Hence , sign damage motor neuron peripheral ( eg . atrophy ) , central ( eg . spasticity ) level . There effective treatment ALS majority patient die within 5 year diagnosis , usually due respiratory failure . Numerous study murine model reveal mesenchymal stem cell ( MSCs ) successfully improve clinical pathological feature ALS patient . The goal nonrandomized , open label study investigate safety tolerability allogeneic Wharton 's jelly-derived mesenchymal stem cell transplantation individual diagnose amyotrophic lateral sclerosis . This clinical trial conduct test therapeutic ( neuroprotective paracrine ) effect allogeneic Wharton 's jelly-derived mesenchymal stem cell ( WJ-MSCs ) . All patient enrol documented history ALS disease prior enrollment . Patients recruit clinical trial 1 year disease diagnosis . Then , patient divide two group : Group I - patient receive intrathecally one application WJ-MSCs Group II - patient receive intrathecally three application ( administration every two month ) WJ-MSCs . Subsequently , allogeneic Wharton 's jelly-derived mesenchymal stem cell transplantation cerebrospinal fluid site spinal cord perform . Finally , treatment safety , adverse event exploratory parameter , include electromyographic ( EMG ) study , force vital capacity ( FVC ) functional rating scale ( FRS ) establish ALS progression rate record throughout duration post-treatment follow period .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>diagnosis ALS disease cell transplantation ( diagnose establish follow El Escorial criterion definite ALS ) good understand protocol willingness consent sign informed consent disease duration : 2 year FVC &gt; 50 % / pulmonologist certificate respiratory function patient cancer , autoimmune disease renal failure , subject respiratory dependent . subject unwilling unable comply requirement protocol pregnancy , breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>